Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06714617 · ClinicalTrials.gov registry record · Phase 1
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Fallopian Tube Cancer, sponsored by SystImmune.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT06714617 is a Phase 1 study of Non-Small Cell Lung Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by SystImmune. The registered enrollment target is 120 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT06714617, a Phase 1 study of Non-Small Cell Lung Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by SystImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
Conditions Studied
Interventions
- DRUG BL-M17D1
Study Locations (9)
Florida
- SCRI-Florida Cancer Center Specialists Lake Mary - Lake Mary
- Hematology Oncology Associates of the Treasure Cost - Port Saint Lucie
- SCRI-Florida Cancer Center Specialists Sarasota - Sarasota
Colorado
- SCRI-Denver HealthOne - Denver
Connecticut
- Yale Cancer Center - New Haven
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- SCRI-Sidney Kimmel Cancer Center - Philadelphia
Tennessee
- SCRI-Oncology Partners - Nashville
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06714617
The ClinicalTrials.gov registry entry for NCT06714617 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which BL-M17D1 is the first listed.
NCT06714617 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06714617 about?
NCT06714617 is a clinical study titled "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors". The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
What is the current status of trial NCT06714617?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-04-10. Estimated completion is 2027-12-01.
What conditions does trial NCT06714617 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer Stage III, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06714617?
The interventions under investigation include: BL-M17D1 (DRUG).
Who is sponsoring clinical trial NCT06714617?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06714617 being conducted?
This trial has 9 study locations across Colorado, Connecticut, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.